Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 17/20 | 0.68 |
| ▸ | KIT | P10721 | 7/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142489 | 0.95 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| Trifluoroacetic Acid SCHEMBL4982624 | 0.93 | CSF1R (0.69) | CSF1RKITCYP3A4NTRK1LCK | |
| Trifluoroacetic Acid SCHEMBL4981726 | 0.93 | CSF1R (0.69) | CSF1RKITCYP3A4NTRK1LCK | |
| Trifluoroacetic Acid SCHEMBL2943105 | 0.92 | CSF1R (0.69) | CSF1RKITCYP3A4NTRK1LCK | |
| Trifluoroacetic Acid SCHEMBL15399627 | 0.91 | CSF1R (0.69) | CSF1RKITCYP3A4NTRK1LCK | |
| Trifluoroacetic Acid SCHEMBL4982365 | 0.90 | CSF1R (0.69) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL13105559 | 0.89 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL13096399 | 0.88 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| Trifluoroacetic Acid SCHEMBL31157981 | 0.88 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL2942044 | 0.88 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697716-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CSF1R 2973/4885KIT 1/4885CYP3A4 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.